Top Markets
Coin of the day
Crossject Société Anonyme Crossject Société Anonyme

Crossject Société Anonyme

ALCJ
Rangering i aksjer #12697
Crossject Société Anonyme develops needle-free injection systems. The company... Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
Aksjekurs
$2.04
Markedsverdi
$122.58M
Endring (1 dag)
4.48%
Endring (1 år)
-1.05%
Land
FR
Handel Crossject Société Anonyme (ALCJ)

Kategori

P/S-forhold for Crossject Société Anonyme (ALCJ)
P/S-forhold per July 2026 TTM: 71.80
Ifølge Crossject Société Anonyme sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 71.80. Ved slutten av 2023 hadde selskapet et P/S-forhold på 1.26K.
P/S-historikk for Crossject Société Anonyme fra 2010 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
2026 (TTM) 71.80 194.15%
2024 24.41 -98.06%
2023 1.26K 911.76%
2022 124.63 55.54%
2021 80.13 434.26%
2020 15.00 -83.59%
2019 91.39 1,279.32%
2018 6.63 -47.30%
2017 12.57 -44.75%
2016 22.76 -47.42%
2015 43.28 8.99%
2014 39.71 -21.42%
2013 50.54 -54.97%
2012 112.23 83.88%
2011 61.03 -69.23%
2010 198.36 0.00%
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
13.31 -81.46%
US
2.65 -96.31%
FR
4.46 -93.79%
DE
9.16 -87.24%
JP
2.57 -96.43%
US